

Remarks

Currently Claims 1-12 are pending.

The specification has been amended to recite the claim of priority and to include an abstract on a separate page.

Claims 1-7 and 9 are amended herein. Claims 1, 2 and 5 are amended to change "or" or "and" and to recite optional substituents for the variables defined therein. Claim 1 is further amended to recite the optional substituents on R³ and to change "can be" to "is". Claim 2 is amended to place the claim in independent form and to change "can be" to "is". Claims 3-7 and 9 are amended to remove multiple dependencies for the purpose of reducing claim fees. Claims 6-7 and 9 are further amended and to remove redundant phrases. Claim 9 is further amended to change "human or animal subject" to "mammal". The foregoing amendments do not narrow the scope of the claims and are not made for purposes of patentability. Support for these amendments can be found throughout Applicants original specification including the original claims and particularly pages 3, lines 34-37 and 5, lines 16-18. No new matter is added.

New claims 10-12 are added. Support for these claims may be found throughout Applicants' specification including the original claims, page 11. No new matter is added.

Applicant respectfully submits that the instant application is in condition for substantive examination, which action is respectfully requested. The Examiner is invited to contact the undersigned at 919 483-8222, to discuss this case further if desired.

Date: 21 March 2005
GlaxoSmithKline
Five Moore Drive, PO Box 13398
Research Triangle Park
North Carolina 27709
(919) 483-8222
fax: (919) 483-7988

Respectfully submitted,



Lorie Ann Morgan
Attorney for Applicants
Registration No. 38,181